213 related articles for article (PubMed ID: 31673932)
21. NPM1 for MRD? Droplet Like It's Hot!
Wertheim GBW; Bagg A
J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
[TBL] [Abstract][Full Text] [Related]
22. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
23. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
[TBL] [Abstract][Full Text] [Related]
24. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M; Pettersson L
APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
[TBL] [Abstract][Full Text] [Related]
25. Biological and clinical consequences of NPM1 mutations in AML.
Heath EM; Chan SM; Minden MD; Murphy T; Shlush LI; Schimmer AD
Leukemia; 2017 Apr; 31(4):798-807. PubMed ID: 28111462
[TBL] [Abstract][Full Text] [Related]
26. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
27. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
Dai Q; Ren Y
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
[TBL] [Abstract][Full Text] [Related]
29. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
[TBL] [Abstract][Full Text] [Related]
30. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
31. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
32. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
Hantel A; Stock W; Kosuri S
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):636-647. PubMed ID: 30006258
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification.
Marcinkowska-Swojak M; Handschuh L; Wojciechowski P; Goralski M; Tomaszewski K; Kazmierczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
Mutat Res; 2016 Apr; 786():14-26. PubMed ID: 26894557
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated
Memoli M; Genthon A; Favale F; Lapusan S; Johnson N; Adaeva R; Deswarte C; Battipaglia G; Malard F; Duléry R; Brissot E; Banet A; Van de Wyngaert Z; Mohty M; Delhommeau F; Legrand O; Hirsch P
Leuk Lymphoma; 2022 Sep; 63(9):2171-2179. PubMed ID: 35459427
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.
Thol F; Kölking B; Damm F; Reinhardt K; Klusmann JH; Reinhardt D; von Neuhoff N; Brugman MH; Schlegelberger B; Suerbaum S; Krauter J; Ganser A; Heuser M
Genes Chromosomes Cancer; 2012 Jul; 51(7):689-95. PubMed ID: 22454318
[TBL] [Abstract][Full Text] [Related]
36. Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis.
Calvo KL; Ojeda MJ; Ammatuna E; Lavorgna S; Ottone T; Targovnik HM; Lo-Coco F; Noguera NI
Eur J Haematol; 2009 Jan; 82(1):69-72. PubMed ID: 18801061
[TBL] [Abstract][Full Text] [Related]
37. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia].
Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632
[TBL] [Abstract][Full Text] [Related]
39. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.
Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F
J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613
[TBL] [Abstract][Full Text] [Related]
40. MRD evaluation of AML in clinical practice: are we there yet?
Freeman SD; Hourigan CS
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):557-569. PubMed ID: 31808906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
